Have a personal or library account? Click to login
Implementing Single-Pill Combination Therapy for Hypertension: A Scoping Review of Key Health System Requirements in 30 Low- and Middle-Income Countries Cover

Implementing Single-Pill Combination Therapy for Hypertension: A Scoping Review of Key Health System Requirements in 30 Low- and Middle-Income Countries

Global Heart
Volume 17 (2022): Issue 1
By: Eleanor Bruyn,  Long Nguyen,  Aletta E. Schutte,  Adrianna Murphy,  Pablo Perel and  Ruth Webster  
Open Access
|Jan 2022

References

  1. 1Campana E, Cunha V, Glaveckaite S, et al. The use of single-pill combinations as first-line treatment for hypertension: Translating guidelines into clinical practice. Journal of Hypertension. 2020; 38: 2369–2377. DOI: 10.1097/HJH.0000000000002598
    Back to article
  2. 2GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. The Lancet (British edition). 2020; 396: 1223–1249.
    Back to article
  3. 3World Health Organization (WHO). Hypertension. Fact sheets 2019.
    Back to article
  4. 4NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet. 2017; 389: 37–55. DOI: 10.1016/S0140-6736(16)31919-5
    Back to article
  5. 5Geldsetzer P, Manne-Goehler J, Marcus M-E, et al. The state of hypertension care in 44 low-income and middle-income countries: A cross-sectional study of nationally representative individual-level data from 1.1 million adults. Lancet. 2019; 394: 652–662. DOI: 10.1016/S0140-6736(19)30955-9
    Back to article
  6. 6Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. Circulation. 2016; 134: 441–450. DOI: 10.1161/CIRCULATIONAHA.115.018912
    Back to article
  7. 7Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study. PLoS Med. 2018; 15: e1002584. DOI: 10.1371/journal.pmed.1002584
    Back to article
  8. 8Salam A, Kanukula R, Atkins E, et al. Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: A systematic review and meta-analysis of randomized controlled trials. Journal of Hypertension. 2019; 37. DOI: 10.1097/HJH.0000000000002096
    Back to article
  9. 9Benjamin IJ, Kreutz R, Olsen MH, et al. Fixed-dose combination antihypertensive medication. The Lancet. 2019; 394: 637–638. DOI: 10.1016/S0140-6736(19)31629-0
    Back to article
  10. 10Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013; 310: 959–968. DOI: 10.1001/jama.2013.184182
    Back to article
  11. 11Corrao G, Nicotra F, Parodi A, et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life ractice. Hypertension. 2011; 58: 566–572. DOI: 10.1161/HYPERTENSIONAHA.111.177592
    Back to article
  12. 12Gradman AH, Parisé H, Lefebvre P, et al. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: A matched cohort study. Hypertension. 2013; 61: 309–318. DOI: 10.1161/HYPERTENSIONAHA.112.201566
    Back to article
  13. 13World Health Organization (WHO). WHO model List of Essential Medicines – 21st list, 2019. Geneva; 2019.
    Back to article
  14. 14Persaud N, Jiang M, Shaikh R, et al. Comparison of essential medicines lists in 137 countries. Bulletin of the World Health Organization. 2019; 97: 394–404C. DOI: 10.2471/BLT.18.222448
    Back to article
  15. 15Bigdeli M, Jacobs B, Tomson G, et al. Access to medicines from a health system perspective. Health Policy and Planning. 2013; 28: 692–704. DOI: 10.1093/heapol/czs108
    Back to article
  16. 16The World Bank. The World by Income and Region. 2020.
    Back to article
  17. 17The World Bank. Population, total. 2019.
    Back to article
  18. 18The Global Health Observatory. Raised blood pressure (SBP>=140 OR DBP>=90) (age-standardized estimate). World Health Organization; 2017.
    Back to article
  19. 19World Health Organization (WHO). National Essential Medicines Lists (NEMLs) Repository. 2019.
    Back to article
  20. 20Resolve to Save Lives. Where we work. n.d.
    Back to article
  21. 21World Health Organization (WHO). Essential Medicines and Health Products Information Portal. 2020.
    Back to article
  22. 22The Hypertension Cardiovascular Outcome Prevention and Evidence in Asia Network. Publications. 2020.
    Back to article
  23. 23Bissell K, Ellwood P, Ellwood E, et al. Essential medicines at the national level: The global asthma network’s essential asthma medicines survey 2014. Int J Environ Res Public Health. 2019; 16: 605. DOI: 10.3390/ijerph16040605
    Back to article
  24. 24Owolabi M, Olowoyo P, Miranda JJ, et al. Gaps in Hypertension Guidelines in Low- and Middle-Income Versus High-Income Countries: A Systematic Review. Hypertension. 2016; 68: 1328–1337. DOI: 10.1161/HYPERTENSIONAHA.116.08290
    Back to article
  25. 25World Health Organization (WHO). Guideline for the pharmacological treatment of hypertension in adults. Geneva; 2021.
    Back to article
  26. 26Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020; 75: 1334–1357. DOI: 10.1161/HYPERTENSIONAHA.120.15026
    Back to article
  27. 27Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension. 2018; 36: 1953–2041. DOI: 10.1097/HJH.0000000000001940
    Back to article
  28. 28Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Soc Hypertens. 2018; 12: 579 e571–579 e573. DOI: 10.1016/j.jash.2018.01.004
    Back to article
  29. 29Okwen PM, Maweu I, Grimmer K, Margarita Dizon J. Evaluation of all African clinical practice guidelines for hypertension: Quality and opportunities for improvement. Journal of Evaluation in Clinical Practice. 2019; 25: 565–574. DOI: 10.1111/jep.12954
    Back to article
  30. 30Aung HY. Update Guidelines in Hypertension. 66th Myanmar Medical Conference. Yangon, Myanmar: Myanmar Society of Hypertension; 2020.
    Back to article
  31. 31Ofori SN, Obosi J. Prevalence of hypertension among office workers in a multi-national company in the Niger-Delta with the 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines. Preventive Medicine Reports. 2019; 15: 100899. DOI: 10.1016/j.pmedr.2019.100899
    Back to article
  32. 32The World Bank. Hypertension care in Ukraine: Breakpoints and implications for action. Washington DC, United States of America: The World Bank; 2018. DOI: 10.1111/jch.13802
    Back to article
  33. 33Sison J, Divinagracia R, Nailes J. Asian management of hypertension: Current status, home blood pressure, and specific concerns in Philippines (a country report). The Journal of Clinical Hypertension. 2020; 22: 504–507.
    Back to article
  34. 34Guidelines for the management of hypertension in Nigeria. In Onwubere B, Kadiri S (eds.) Nigerian Hypertension Society Guidelines Committee. Enugu, Nigeria: Ezu Books Limited. 2005. pp. 1–4.
    Back to article
  35. 35Olowofela A, Isah AO. Antihypertensive medicines prescriptions before and after the Nigeria Hypertension Society guidelines and prescriber’s awareness of the guideline. Nigerian Medical Journal. 2017; 58: 107–113. DOI: 10.4103/nmj.NMJ_131_16
    Back to article
  36. 36World Health Organization (WHO). WHO model list of essential medicines – 21st list. Geneva; 2019.
    Back to article
  37. 37Webster R, Murphy A, Bygrave H, et al. Implementing fixed dose combination medications for the prevention and control of cardiovascular diseases. Global Heart. 2020; 15: 57–62. DOI: 10.5334/gh.860
    Back to article
  38. 38Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: A simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010; 4: 115–125. DOI: 10.2147/PPA.S10330
    Back to article
  39. 39World Health Organization (WHO). HEARTS technical package for cardiovascular disease management in primary health care: Access to essential medicines and technology. Geneva; 2018.
    Back to article
  40. 40Abdelgadir HS, Elfadul MM, Hamid NH, Noma M. Adherence of doctors to hypertension clinical guidelines in academy charity teaching hospital, Khartoum, Sudan. BMC Health Services Research. 2019; 19: 309. DOI: 10.1186/s12913-019-4140-z
    Back to article
  41. 41Milchak JL, Carter BL, James PA, Ardery G. Measuring adherence to practice guidelines for the management of hypertension. Hypertension. 2004; 44: 602–608. DOI: 10.1161/CIRCRESAHA.118.313220
    Back to article
  42. 42Burnier M, Egan BM. Adherence in hypertension. Circulation Research. 2019; 124: 1124–1140.
    Back to article
  43. 43Macquart de Terline D, Kane A, Kramoh KE, et al. Factors associated with poor adherence to medication among hypertensive patients in twelve low and middle income Sub-Saharan countries. PloS one. 2019; 14: e0219266–e0219266. DOI: 10.1371/journal.pone.0219266
    Back to article
  44. 44Pharm’Net. Liste des médicaments. Algeria: Pharm’Net; 2020.
    Back to article
  45. 45e-Pharma. High blood pressure. Kinshasa, Democratic Republic of Congo: e-Pharmacie; 2020.
    Back to article
  46. 46Ibrahim MM. The Egyptian Hypertension Society: Egyptian Hypertension Guidelines. Egyptian Heart Journal. 2014; 66: 79–132. DOI: 10.1016/j.ehj.2014.03.001
    Back to article
  47. 47Rosheta. Cardiovascular System. Egypt: Rosheta; 2020.
    Back to article
  48. 48World Health Organization (WHO). Food Medicine and Healthcare Administration and Control Authority of Ethiopia. National Essential Medicine List: Fifth Edition. Addis Ababa: World Health Organization; 2015.
    Back to article
  49. 49Ministry of Health. Ethiopian National Guideline on Major NCDs 2016. Addis Ababa, Ethiopia; 2016.
    Back to article
  50. 50Drug Administration and Control Authority of Ethiopia. National Drug Formulary of Ethiopia. Addis Ababa, Ethiopia: Planning, Drug Information Establishment and Distribution Department; 2007.
    Back to article
  51. 51Shukrala F, Gabriel T. Assessment of prescribing, dispensing, and patient use pattern of antihypertensive drugs for patients attending outpatient department of Hiwot Fana Specialized University Hospital, Harar, Eastern Ethiopia. Drug Des Devel Ther. 2015; 9: 519–523. DOI: 10.2147/DDDT.S73670
    Back to article
  52. 52Ministry of Health. Kenya Essentials Medicines List 2019. Nairobi, Kenya; 2019.
    Back to article
  53. 53Ministry of Health. Kenya National Guidelines For Cardiovascular Diseases Management. Nairobi, Kenya: Division of Non-Communicable Diseases; 2018.
    Back to article
  54. 54MYDAWA. Anti-Hypertensives. Nairobi, Kenya; 2020.
    Back to article
  55. 55Rida E, Soulaymani A, Serhier Z, Hami H, Abdelrhani M. Antidiabetics and antihypertensive medications use in Morocco: A pharmacoepidemiological descriptive study. African Journal of Primary Health Care & Family Medicine. 2020; 12. DOI: 10.4102/phcfm.v12i1.2195
    Back to article
  56. 56Berrada G, Ahid S, Ghanname I, et al. Generic drugs and the consumption trends of antihypertensives in Morocco. Thérapie. 2013; 68: 303–312.
    Back to article
  57. 57Asset Chemist. High Blood Pressure (Cardiovascular). Nigeria; 2020.
    Back to article
  58. 58Hypertension guideline working group, Seedat YK, Rayner BL, Veriava Y. South African hypertension practice guideline 2014. Cardiovascular Journal of Africa. 2014; 25: 288–294. DOI: 10.5830/CVJA-2014-062
    Back to article
  59. 59Schellack N, Malan L. An overview of fixed-dose combinations of antihypertensive drugs in South Africa. South African Family Practice. 2014; 56: 206–211. DOI: 10.1080/20786190.2014.953868
    Back to article
  60. 60Federal Ministry of Health. National Essential Medicines List. Sudan; 2014.
    Back to article
  61. 61Federal Ministry of Health. Sudan National Standard Treatment Guidelines. Sudan; 2014.
    Back to article
  62. 62The Ministry of Health CD, Gender, Elderly and Children. Standard Treatment Guidelines & National Essential Medicines List Tanzania Mainland. 2017.
    Back to article
  63. 63Rimoy GH, Justin-Temu M, Nilay C. Prescribing patterns and cost of antihypertensive drugs in private hospitals in Dar es Salaam, Tanzania. East and Central African Journal of Pharmaceutical Sciences. 2009; 11. DOI: 10.4314/ecajps.v11i3.46285
    Back to article
  64. 64Ministry of Health. Uganda Clinical Guidelines 2016: National Guidelines for Management of Common Conditions. Kamala, Uganda; 2016.
    Back to article
  65. 65PinePharmacy. Tablets and capsules. Uganda; 2020.
    Back to article
  66. 66Ministry of Public Health of the Islamic Republic of Afghanistan. National Standard Treatment Guidelines for the Primary Level. Afghanistan; 2013.
    Back to article
  67. 67Ministry of Public Health, General Directorate of Pharmaceutical Affairs, Avicenna Pharmaceutical Institute. National Essential Medicines List of Afghanistan. 2014.
    Back to article
  68. 68Directorate General of Health Services MoHaFA. National Guidelines for Management of Hypertension in Bangladesh. In Malik A (ed.) Bangladesh; 2013.
    Back to article
  69. 69BanglaMeds. Health Store. Dhaka, Bangladesh; 2020.
    Back to article
  70. 70Joint Committee for Guideline Revision. 2018 Chinese guidelines for prevention and treatment of hypertension – a report of the revision committee of Chinese guidelines for prevention and treatment of hypertension. Journal of Geriatric Cardiology. 2019; 16: 182–241.
    Back to article
  71. 71Tpl. BRIEF—China approves first generic Exforge. London: The Pharma Letter; 2020.
    Back to article
  72. 72Ministry of Health & Family Welfare. Standard Treatment Guidelines – Hypertension. Government of India; 2015.
    Back to article
  73. 73Gupta R, Malhotra A, Malhotra P. Assessment of rational use of fixed dose combinations in hypertension in a tertiary care teaching hospital in north India. International Journal of Advances in Medicine. 2018; 5. DOI: 10.18203/2349-3933.ijam20183905
    Back to article
  74. 74Medlife. Search results for Hydrochlorothiazide. India: Medlife; 2020.
    Back to article
  75. 75Indonesian Society of Hypertension. Konsensus Penatalaksanaan Hipertensi 2019. In Lukito AA, Harmeiwaty E, Hustrini NM (eds.) Jakarta, Indonesia; 2019.
    Back to article
  76. 76Hatala R, Pella D, Hatalová K, Šidlo R. Optimization of blood pressure treatment with fixed-combination perindopril/amlodipine in patients with arterial hypertension. Clinical Drug Investigation. 2012; 32: 603–612. DOI: 10.2165/11634530-000000000-00000
    Back to article
  77. 77K24Klik. Product Kategori: Sistem Kardiovaskuler & Hematopoietik. Indonesia; 2020.
    Back to article
  78. 78My-Medicine. Hypertension, Heart & Artery Disease. Myanmar; 2020.
    Back to article
  79. 79Pakistan Hypertension League. 3rd National Hypertension Guideline: For the prevention, detection, evaluation & management of hypertension. Pakistan Hypertension League; 2018.
    Back to article
  80. 80MedOnline. Prescription Drugs. Pakistan: MedOnline; 2020.
    Back to article
  81. 81RosePharmacy. Rose Pharmacy Generics. Subangdaku Mandaue City, Philippines: Rose Pharmacy; 2020.
    Back to article
  82. 82Thai Hypertension Society. 2019 Thai Guidelines on The Treatment of Hypertension. 2019.
    Back to article
  83. 83Phimda K, Limpaiboon R, Sattayasai J. Management of hypertension in the general practice clinic: Post-marketing surveillance with a fixed combination of perindopril and indapamide. Srinagarind Medical Journal. 2009; 24: 308–313.
    Back to article
  84. 84Association VNH. Hypertension diagnosis and treatment guidelines 2018. Vietnam National Heart Association; 2018.
    Back to article
  85. 85JioHealth. Thuc huyt áp- tim mch, thuc li tiu. Ho Chi Minh City, Vietnam: Jio Health; 2020.
    Back to article
  86. 86Cabinet Ministers of Ukraine. National List of Essential Medicines. Kyiv; 2017.
    Back to article
  87. 87Mishchenko O, Iakovlieva L, Adonkina V. Pharmacoeconomic evaluation of fixed-dose triple combination for antihypertensive therapy in Ukraine. Journal of Health Policy and Outcomes Research. 2014; 1: 66–75.
    Back to article
  88. 88Iakovlieva L, Mishchenko O, Gerasymova O, et al. Evaluation the feasibility of some schemes of antihypertensive therapy on the budget impact analysis and missed opportunities analysis in Ukraine. Value in Health. 2013; 16: PA279. DOI: 10.1016/j.jval.2013.03.1447
    Back to article
  89. 89Chazova IE, Zhernakova, YV Z, on behalf of the experts. Clinical guidelines: Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019; 16: 6–31. DOI: 10.26442/2075082X.2019.1.190179
    Back to article
  90. 90Bochkareva EV, Butina EK, Kim IV, et al. Adherence to antihypertensive medication in Russia: A scoping review of studies on levels, determinants and intervention strategies published between 2000 and 2017. Arch Public Health. 2019; 77: 43–43. DOI: 10.1186/s13690-019-0366-9
    Back to article
  91. 91Soboleva MS, Loskutova EE. Analysis of preferences in the use of fixed-doses combinations antihypertensive drugs in the regions of far-eastern federal district. ClinicoEconomics and Outcomes Research. 2020; 12: 265–272. DOI: 10.2147/CEOR.S251721
    Back to article
  92. 92Sociedad Argentina de Hipertensión Arterial. Consenso Argentino de Hipertensión Arterial. 2018.
    Back to article
  93. 93Espeche W, Salazar MR, Sabio R, et al. Adherence to antihypertensive drug treatment in Argentina: A multicenter study. The Journal of Clinical Hypertension. 2020; 22: 656–662. DOI: 10.1111/jch.13830
    Back to article
  94. 94Farmacity. Resultados: Valsartan. Buenos Aires, Argentina: farmacity; 2020.
    Back to article
  95. 95Arquivos Brasileiros de Cardiologia. 7th Brazilian Guideline of Arterial Hypertension. Arquivos Brasileiros de Cardiologia; 2016.
    Back to article
  96. 96Mengue SS, Bertoldi AD, Ramos LR, et al. Access to and use of high blood pressure medications in Brazil. Rev Saude Publica. 2016; 50: 8s–8s. DOI: 10.1590/s1518-8787.2016050006154
    Back to article
  97. 97Ultrafarma. Pressão Alta. São Paulo, Brazil: ultrafarma; 2020.
    Back to article
  98. 98Gobierno de Colombia. Guía de Práctica Clínica: Para el manejo de la hipertensión arterial primaria. In Salud IdETe (ed.) Bogotá, Colombia; 2017.
    Back to article
  99. 99Cruz Verde. Cardiovasculares. Bogota, Mexico: Cruz Verde; 2020.
    Back to article
  100. 100Centro Nacional de Excelencia Tecnologica en Salud. Diagnostico y Tramtamiento de la Hipertension arterial en el Primer nivel de atencion. Mexico: Instituto Mexicano del Seguro Social; 2014.
    Back to article
  101. 101MEXI Pharmacy. Results for: ‘hydrochlorothiazide’. Mexico: MEXI Pharmacy; 2020.
    Back to article
  102. 102Noohi F, Sarrafzadegan N, Khosravi A, Andalib E, Group FRoHBPW. The first Iranian recommendations on prevention, evaluation and management of high blood pressure. ARYA Atheroscler. 2012; 8: 97–118.
    Back to article
  103. 103Directorate of Public Health. National Guidelines for Primary Health Care Physicians: Hypertension Prevention, Diagnosis and Treatment. Iraq: Directorate of Public Health Non-communicable Disease Section; 2012.
    Back to article
  104. 104Nassr OA, Forsyth P. Evaluation of blood pressure control and associated factors among patients with hypertension in Iraq: A prospective cross-sectional study. J Pharm Bioallied Sci. 2019; 11: 232–239. DOI: 10.4103/jpbs.JPBS_82_19
    Back to article
  105. 105Aydogdu S, Guler K, Bayram F, et al. 2019 Turkish Hypertension Consensus Report. Turk Kardiyoloji Dernegi Arsivi. 2019; 47: 535–546. DOI: 10.5543/tkda.2019.62565
    Back to article
  106. 106Abaci A, Kozan O, Oguz A, et al. Prescribing pattern of antihypertensive drugs in primary care units in Turkey: Results from the TURKSAHA study. European Journal of Clinical Pharmacology. 2007; 63: 397–402. DOI: 10.1007/s00228-007-0266-8
    Back to article
DOI: https://doi.org/10.5334/gh.1087 | Journal eISSN: 2211-8179
Journal RSS Feed
Language: English
Submitted on: Jul 9, 2021
Accepted on: Dec 3, 2021
Published on: Jan 25, 2022
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
KEYWORDS,
Single-pill combination,
antihypertensives,
hypertension,
low- and middle-income countries,
essential medicines list,
hypertension treatment guidelines,
high blood-pressure

© 2022 Eleanor Bruyn, Long Nguyen, Aletta E. Schutte, Adrianna Murphy, Pablo Perel, Ruth Webster, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 17 (2022): Issue 1Next article